Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 19 Jan 2024
Voydeya (danicopan) granted first ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy
19 January 2024 - Approval of first in class, oral, factor D inhibitor based on ALPHA Phase 3 trial in ...
Posted by Michael Wonder on 19 Jan 2024
US FDA grants mesoblast rare paediatric disease designation for Revascor (Rexlemestrocel-L) in children with congenital heart disease
19 January 2024 - Revascor increases size of left heart chamber and improves surgical outcomes in children with hypoplastic left ...
Posted by Michael Wonder on 18 Jan 2024
Verastem Oncology granted fast track designation for combination of avutometinib and sotorasib for the treatment of KRAS G12C mutant non-small-cell lung cancer
18 January 2024 - On-going RAMP 203 trial assessing a more complete vertical blockade with RAF/MEK and KRAS G12C inhibition along ...
Posted by Michael Wonder on 18 Jan 2024
UtilityTherapeutics announces FDA acceptance of PIVYA new drug application with priority review
17 January 2024 - Utility has received a Prescription Drug User Fee Act target action date of 24 April 2024. ...
Posted by Michael Wonder on 18 Jan 2024
UCB announces MHRA approval for UCB’s Zilbrysq
18 January 2024 - Green light concerns generalised myasthenia gravis therapy ...
Posted by Michael Wonder on 18 Jan 2024
Drug makers raise prices of Ozempic, Mounjaro and hundreds of other drugs
18 January 2024 - Companies hiked prices of 775 brand name drugs at start of new year. ...
Posted by Michael Wonder on 18 Jan 2024
New orphan drug for a sub-type of acute myeloid leukaemia: G-BA sees significant additional benefit
18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...
Posted by Michael Wonder on 18 Jan 2024
US FDA declines to approve Shin Nippon Biomedical's migraine drug
17 January 2024 - The US health regulator has declined to approve Japan-based Shin Nippon Biomedical Laboratories' treatment for acute ...
Posted by Michael Wonder on 18 Jan 2024
Updates to the HTA Policy and Methods Review Reference Committee (18 January 2024)
18 January 2024 - Communiques for three HTA Review Reference Committee meetings held in December 2023 are now available. ...
Posted by Michael Wonder on 18 Jan 2024
Sudbury, Ontario family finally gets coverage for drug to treat daughter's rare epilepsy
16 January 2024 - Fenfluramine costs more than $3,000 a month and is not approved by Health Canada. ...
Posted by Michael Wonder on 18 Jan 2024
Health Canada approves Uplinza (inebilizumab) for the treatment of neuromyelitis optica spectrum disorders
16 January 2024 - First and only anti-CD19 B-cell-depleting monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders ...
Posted by Michael Wonder on 17 Jan 2024
Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology and competition
17 January 2024 - We aimed to identify and quantify factors associated with launch prices and post-launch price changes of ...
Posted by Michael Wonder on 17 Jan 2024
Prescription Drug Affordability Act aims to set limits on high medication prices
17 January 2024 - Lawmakers in Springfield are focusing on high prescription drug prices. ...
Posted by Michael Wonder on 17 Jan 2024
Dupixent (dupilumab) US label updated with data further supporting use in atopic dermatitis with moderate to severe hand and foot involvement
16 January 2024 - Data included from first and only Phase 3 trial specifically evaluating a biologic in this difficult to ...
Posted by Michael Wonder on 17 Jan 2024
PBAC - 2023 in review
18 January 2024 - In contrast to New Zealand, 2023 saw many new medicines listed on the PBS. ...